158 related articles for article (PubMed ID: 38197309)
21. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma.
Chen Z; Zou Y; Zhang Y; Chen Z; Wu F; Jin H; Shi N
Dis Markers; 2022; 2022():8109771. PubMed ID: 35047095
[TBL] [Abstract][Full Text] [Related]
22. Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response.
Wei Y; Lan C; Yang C; Liao X; Zhou X; Huang X; Xie H; Zhu G; Peng T
Sci Rep; 2023 Sep; 13(1):14519. PubMed ID: 37666920
[TBL] [Abstract][Full Text] [Related]
23. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma.
Wang Z; Chen X; Zhang J; Chen X; Peng J; Huang W
Front Immunol; 2023; 14():1204338. PubMed ID: 37680641
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
25. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
Hong W; Zhang Y; Wang S; Zheng D; Hsu S; Zhou J; Fan J; Zeng Z; Wang N; Ding Z; Yu M; Gao Q; Du S
Cancer Lett; 2024 Feb; 582():216594. PubMed ID: 38135208
[TBL] [Abstract][Full Text] [Related]
26. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
27. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
28. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
Wang S; Gao S; Shan L; Qian X; Luan J; Lv X
PeerJ; 2023; 11():e14691. PubMed ID: 36650832
[TBL] [Abstract][Full Text] [Related]
30. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
32. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
33. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
34. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
35. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.
Xiao J; Liu T; Liu Z; Xiao C; Du J; Zuo S; Li H; Gu H
Cells; 2022 Jul; 11(15):. PubMed ID: 35892599
[TBL] [Abstract][Full Text] [Related]
36. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
[TBL] [Abstract][Full Text] [Related]
38. A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma.
Hui Y; Leng J; Jin D; Liu D; Wang G; Wang Q; Wang Y
Dis Markers; 2021; 2021():1986159. PubMed ID: 34721731
[TBL] [Abstract][Full Text] [Related]
39. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
40. Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma.
Tang H; Yang Q; Tang Q; Li X; Ding W; Chen W
Comput Biol Med; 2022 Sep; 148():105886. PubMed ID: 35973372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]